The sum is greater than the FGFR1 partner

Department of Pediatrics and Comprehensive Cancer Center, University of California San Fransisco, San Francisco, CA 94143 USA.
Cancer Cell (Impact Factor: 23.52). 04/2004; 5(3):203-4. DOI: 10.1016/S1535-6108(04)00060-1
Source: PubMed


Cancer-associated chromosomal translocations create chimeric oncoproteins that contribute to aberrant growth by dominant or dominant negative mechanisms. Interestingly, genes such as MLL, RARA, and EWS are fused to multiple partners. This molecular promiscuity can provide important functional information, as specific translocations may be associated with discrete clinical and molecular features. In this issue of Cancer Cell, use a murine retroviral transduction/transplantation system to analyze two FGFR1 fusions found in hematologic malignancies. Their results show that these chromosomal rearrangements play a central role in pathogenesis, underscore the role of partner genes in modulating disease phenotypes, and uncover potential therapeutic targets.

5 Reads
  • Source
    • "These encode the RNA - binding protein LSM1 ( Fraser et al . , 2005 ) , the receptor tyrosine kinase FGFR1 ( Braun and Shannon , 2004 ) , the cell - cycle - regulatory protein TACC1 ( Still et al . , 1999 ) , the metalloproteinase ADAM9 ( Maz - zocca et al . "
    [Show abstract] [Hide abstract]
    ABSTRACT: This study explores the roles of genome copy number abnormalities (CNAs) in breast cancer pathophysiology by identifying associations between recurrent CNAs, gene expression, and clinical outcome in a set of aggressively treated early-stage breast tumors. It shows that the recurrent CNAs differ between tumor subtypes defined by expression pattern and that stratification of patients according to outcome can be improved by measuring both expression and copy number, especially high-level amplification. Sixty-six genes deregulated by the high-level amplifications are potential therapeutic targets. Nine of these (FGFR1, IKBKB, ERBB2, PROCC, ADAM9, FNTA, ACACA, PNMT, and NR1D1) are considered druggable. Low-level CNAs appear to contribute to cancer progression by altering RNA and cellular metabolism.
    Cancer Cell 01/2007; 10(6):529-41. DOI:10.1016/j.ccr.2006.10.009 · 23.52 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Fibroblast growth factor 2 (FGF-2) and its main receptor FGFR1 have been shown to promote hepatic stellate cell (HSC) activation and proliferation. However, scant information is available on the anti-fibrogenic activity of FGFR1 inhibitors. The aim of this study was to assess the impact of a selective FGFR1 tyrosine kinase inhibitor NP603 on HSC proliferation and hepatic fibrosis. We demonstrated that rat primary HSCs secreted significant amounts of FGF-2, and its tyrosine phosphorylation of FGFR1 was attenuated by NP603. NP603 inhibited HSC activaton by measuring the expression of α-smooth muscle actin (α-SMA) and the production of type I collagen using ELISA. Furthermore, NP603 (25 μM) in vitro strongly suppressed HSC growth induced by FGF-2 (10 ng/ml) and FCS. This effect correlated with the suppression of extracellular-regulated kinase (ERK) activity and its downstream targets cyclin D1 and p21. In addition, PO NP603 (20 mg·kg(-1)·day(-1)) administration significantly decreased hepatic collagen deposition and α-SMA expression in CCl(4)-treated rats. Collectively, these studies suggest that selective blocking of the FGFR1-mediated pathway could be a promising therapeutic approach for the treatment of hepatic fibrosis.
    AJP Cell Physiology 05/2011; 301(2):C469-77. DOI:10.1152/ajpcell.00452.2010 · 3.78 Impact Factor


5 Reads
Available from